...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Breast cancer >Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes
【24h】

Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes

机译：更年期期间的体重指数和更年期疾病影响接受阿那曲唑治疗的日本绝经后乳腺癌患者的血管舒缩症状：一项针对患者报告结局的前瞻性多中心队列研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Adverse events related to endocrine therapies have a major impact not only on patients’ quality of life but also on treatment discontinuation. Although vasomotor symptoms induced by aromatase inhibitors are frequently recognized, risk factors, especially for Japanese women, are not well reported. To identify risk factors for vasomotor symptoms of Japanese breast cancer patients treated with adjuvant anastrozole, we conducted a prospective cohort study based on patient-reported outcomes (PROs).Patients and methodsFor this prospective cohort study (SAVS-JP, UMIN000002455), 391 postmenopausal Japanese estrogen receptor-positive breast cancer patients who were treated with adjuvant anastrozole were recruited from 28 centers. The PRO assessment was obtained from a self-reported questionnaire at baseline, 3, 6, 9 and 12?months between August 2009 and April 2012. Vasomotor symptoms, comprising hot flashes, night sweats, and cold sweats, were categorized into four grades (none, Grade 1: mild, Grade 2: moderate, Grade 3: severe). Pre-existing symptoms were only included if they had become worse than at baseline.ResultsHot flashes, night sweats, and cold sweats at baseline were reported by 20.5, 15.1, and 8.2?% of the patients, respectively, and new appearance or worsening of symptoms in comparison with baseline by 38.4, 29.3, and 28.7?%, respectively. About 80?% of newly occurring symptoms were Grade 1, and less than 5?% were Grade 3. Vasomotor symptoms were reported by 201 out of 362 patients (55.5?%) during the first year and the mean time to onset was 5.6?months. Patients with vasomotor symptoms were significantly younger (mean 62.8?years, range 38–86 vs 64.7?years, range 37–84; p?=?0.02), had higher body mass index (BMI) (23.4?kg/m2, range 15.8–39.9 vs 22.4?kg/m2, range 15.8–34.9; p?=?0.01), had vasomotor symptoms sooner after menopause (12.4?years, range 0–51 vs 15.1?years, range 1–37; p?=?0.002), and had more menopausal disorders during menopause (63.3 vs 36.7?%; p?=?0.002). Multivariate analysis showed that BMI [odds ratio (OR) 1.09 per unit of increase, 95?% confidence interval (CI) 1.02–1.16; p?=?0.009] and experiencing menopausal disorders (OR 2.11, 95?% CI 1.35–3.30; p?=?0.001) were significantly associated with vasomotor symptoms.ConclusionHigh BMI and experiencing menopausal disorders at menopause were found to be significantly associated with the occurrence of vasomotor symptoms. These findings are expected to prove useful for the management of postmenopausal Japanese women treated with aromatase inhibitors.
机译：背景与内分泌疗法有关的不良事件不仅对患者的生活质量有重大影响，而且对治疗中断也有重大影响。尽管人们经常认识到由芳香化酶抑制剂引起的血管舒缩症状，但危险因素，尤其是日本女性的危险因素，尚未得到充分报道。为了确定接受阿那曲唑辅助治疗的日本乳腺癌患者血管舒缩症状的危险因素，我们根据患者报告的结局（PRO）进行了一项前瞻性队列研究。患者和方法该前瞻性队列研究（SAVS-JP，UMIN000002455），绝经后为391从28个中心招募了接受辅助阿那曲唑治疗的日本雌激素受体阳性乳腺癌患者。 PRO评估是从2009年8月至2012年4月的基线，第3、6、9和12个月的自我报告调查表中获得的。血管舒缩症状包括潮红，盗汗和冷汗，分为四个等级（无，等级1：轻度，等级2：中度，等级3：严重）。仅在原有症状比基线恶化时才包括先前存在的症状。结果分别有20.5％，15.1％和8.2％的患者报告基线出现潮热，盗汗和冷汗，并且新出现或恶化症状与基线相比分别下降了38.4％，29.3％和28.7％。在第一年中，362名患者中有201名报告了血管舒缩症状（55.5％），其中约80％的新出现的症状是1级，不到5％的是3级。个月。具有血管舒缩症状的患者明显年轻（平均年龄为62.8岁，范围38-86岁，相对于64.7岁，范围37-84岁; p？=？0.02），具有更高的体重指数（BMI）（23.4岁kg / m2，范围）。 15.8–39.9 vs 22.4？kg / m2，范围15.8–34.9; p？=？0.01），绝经后较早出现血管舒缩症状（12.4？年，范围0–51 vs 15.1？年，范围1–37; p？= ≤0.002），并且在绝经期间有更年期障碍（63.3比36.7％; p = 0.002）。多变量分析显示，BMI [比值比（OR）为1.09，每增加一单位，95％置信区间（CI）为1.02-1.16; p？=？0.009]和更年期疾病（OR 2.11，95％CI 1.35–3.30; p？=？0.001）与血管舒缩症状显着相关。结论高BMI和更年期经历的更年期疾病与血管舒缩症状显着相关。血管舒缩症状的发生。这些发现有望证明对用芳香化酶抑制剂治疗的绝经后日本妇女的治疗有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号